Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Post by 19LDS84on Jan 13, 2020 4:48pm
150 Views
Post# 30548248

Incompetence

Incompetence This is once again a clear sign of just how incompetent this team really is. Just add this plunder to the pile. If there was a mistake made with these 5 groups. Wow how incompetent to make such a mistake. If it was a reporting issues wow how incompetent to make such a mistake. If it was the company running the trials. Wow how incompetent. If if if if.... it doesnt matter how many times I read this release all I read is incompetence that is gonna hurt the company on every level. Why would the FDA even consider an approval when the trials had what appears to be a major problem? I could be wrong but the FDA is supposed to make sure these processes were run smoothly and properly.... not "oh hey we had great results except for this giant anomaly over here. Would you mind just ignoring that and push the drug through???" Oh.... " whats that? You want us to redo the entire process start to finish?" This is what I think we're all in for now. I cannot see the FDA approving this. We're all hoping for some miracle perfect explanation that proves the drug better and proves acasti's team competent. Not impossible, just not likely. I don't know about you but I need a drink. GLTA
Bullboard Posts